Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > ACADEMIA
ACADEMIA
- No Problems Found with Integrity of CASE-J Data Analyses: Kyoto Univ.
March 2, 2015
- Govt-Backed Research Center Looks to License Malaria Vaccine to Mega Pharma
February 27, 2015
- Keio Researcher to Launch Clinical Trial on Repositioned AD Treatment in April
February 9, 2015
- Yamagata Univ. Hospital Introduces Anticancer Agent Dispensing Robot
January 23, 2015
- Nagoya University Concludes Diovan Study Data Trustworthy
December 24, 2014
- AGs Could Hinder Optimization of Healthcare Spending, Reduce Patients’ Options: Prof. Sakamaki
December 24, 2014
- Jikei Concludes Event Data Unnatural in Diovan Study
December 15, 2014
- British Medical Journal Retracts Sub-Analysis Paper of VART Study
December 11, 2014
- Cancer Researchers Call for Academia-Industry Collaboration via Japan NIH
December 9, 2014
- 22 Seeds Supported by Drug Discovery Support Network So Far: Dr Kurebayashi of NIBIO
December 9, 2014
- AIDS Treatment Extends Lives, but Many Problems Remain: Dr Mitsuya
December 1, 2014
- J-ARF Moving Into Full Gear as Academic Research Organization
December 1, 2014
- Next Year to See “Dawn of New Age” of Interferon-Free Hepatitis C Treatment: Dr Kumada
November 28, 2014
- Avigan’s Efficacy in Ebola “Unknown” with No Corroborative Data: NIID Official
November 27, 2014
- J-CLEAR’s Kuwajima Criticizes Plan to Legally Regulate Clinical Research
November 12, 2014
- ICH-GCP Compliance Obligatory for Clinical Studies Conducted by Chiba University
October 28, 2014
- Chiba University Issues Warning to Prof. Involved in VART Study
October 28, 2014
- JSH to Draft Guidelines on Clinical Research with Company Funding
October 21, 2014
- St. Marianna Hospital Elbows Drug Makers to Reveal Detailing Costs Embedded in Drug Prices
October 10, 2014
- Japanese Society of Hypertension Announces Resignation of President
October 1, 2014
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…